Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients
Status:
Withdrawn
Trial end date:
2021-03-25
Target enrollment:
Participant gender:
Summary
Combination immune checkpoint inhibitor and DNA vaccine will result in clearance of HPV DNA
biomarkers (oral and/or plasma) for patients with persistent HPV-16 E6/E7 DNA (HPV biomarker)
after treatment with curative intent.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins